SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. , a leading RNAi therapeutics company, announced today that it will release third quarter financial results for the period ended September 30, 2005 before U.S. financial markets open on Thursday, November 3, 2005.
Howard W. Robin, Sirna President and CEO, and the Sirna senior management team will discuss progress to date in their clinical and preclinical programs, the recently announced strategic alliance with Allergan, and provide an update on third quarter financial results during a conference call on Thursday, November 3rd at 8:30 a.m. EST (6:30 a.m. MST; 5:30 a.m. PST).
A live audio webcast of the call will be available at the Company’s corporate web site at www.sirna.com. Participants are urged to log on to the web site 15 minutes prior to the scheduled start time to download and install any necessary audio software. To access the live telephonic broadcast, domestic callers should dial (800) 289-0572; international callers may dial (913) 981-5543.
An audio webcast replay will be available on Sirna’s web site, www.sirna.com, for 60 days. Additionally, a telephonic replay of the call will be maintained through midnight, Thursday, November 17, 2005. To access the replay, please dial (888) 203-1112 from the U.S. or (719) 457-0820 when calling internationally, using confirmation code 9542519.
About Sirna Therapeutics
Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington’s disease, diabetes and oncology. Sirna Therapeutics has presented interim Phase 1 clinical trial data for its most advanced compound, Sirna-027, a chemically optimized siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD. Sirna-027, which has been partnered with Allergan, Inc., has been shown to be safe and well tolerated with a trend toward visual acuity improvement and demonstrated biological activity. Sirna has a leading intellectual property portfolio in RNAi with 45 issued patents and over 250 pending applications worldwide. More information on Sirna Therapeutics is available on the Company’s web site at http://www.sirna.com/.
Contacts: Rebecca Galler Robison, Senior Director, Corporate Strategy of Sirna Therapeutics, Inc., +1-303-449-6500 Francesca DeMartino (investors) or Jason Rando (media), both of The Ruth Group, +1-646-536-7024 / 7025
Sirna Therapeutics, Inc.
CONTACT: Rebecca Galler Robison, Senior Director, Corporate Strategy ofSirna Therapeutics, Inc., +1-303-449-6500; or Investors, FrancescaDeMartino, +1-646-536-7024, or Media, Jason Rando, +1-646-536-7025, both ofThe Ruth Group, for Sirna Therapeutics, Inc.
Web site: http://www.sirna.com/
